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ABSTRACT 
 Determination of hepatitis C virus (HCV) genotypes plays an important 
role in the direct-acting agent era. Discrepancies between HCV genotyping 
and serotyping assays are occasionally observed. Eighteen samples with 
discrepant results between genotyping and serotyping methods were analyzed. 
HCV serotyping and genotyping were based on the HCV nonstructural 4 
(NS4) region and 5'-untranslated region (5'-UTR), respectively. HCV core and 
NS4 regions were chosen to be sequenced and were compared with the 
genotyping and serotyping results. Deep sequencing was also performed for 
the corresponding HCV NS4 regions. Seventeen out of 18 discrepant samples 
could be sequenced by the Sanger method. Both HCV core and NS4 
sequences were concordant with that of genotyping in the 5'-UTR in all 17 
samples. In cloning analysis of the HCV NS4 region, there were several amino 
acid variations, but each sequence was much closer to the peptide with the 
same genotype. Deep sequencing revealed that minor clones with different 
subgenotypes existed in two of the 17 samples. Genotyping by genome 
amplification showed high consistency, while several false reactions were 
detected by serotyping. The deep sequencing method also provides accurate 
genotyping results and may be useful for analyzing discrepant cases. HCV 
genotyping should be correctly determined before antiviral treatment. 
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LIST OF ABBREVIATIONS 
HCV  Hepatitis C virus 
NS  Nonstructural 
5'-UTR 5'-untranslated region 
RNA  Ribonucleic acid 
cDNA Complementary deoxyribonucleic acid 
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ALT  Alanine transaminase 
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1. INTRODUCTION 
 Hepatitis C virus (HCV) is a positive-stranded RNA virus ~9.6 kb in 
length, and it belongs to the genus Hepacivirus within the Flaviviridae family 
[1]. It is estimated that 170 million people worldwide are chronically infected 
with HCV and at risk of liver fibrosis, cirrhosis and hepatocellular carcinoma 
[2]. The HCV genome encodes at least three structural proteins: core and two 
envelope glycoproteins (E1 and E2); and seven nonstructural (NS) proteins 
(p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). 
 Globally, at least 7 HCV genotypes and 67 subtypes have been 
characterized. HCV isolates differ by >15% among different genotypes or 
subtypes [3]. HCV genotypes and subtypes are distributed differently among 
different areas of the world. In Japan, HCV genotype 1b is the major genotype 
(70%), followed by HCV genotype 2a (20%) and 2b (10%) [4,5]. Several 
methods have been established to determine HCV genotypes, such as 
sequence analysis [6], restriction fragment length polymorphism [7], 
hybridization of PCR products with specific probes [8] and next-generation 
sequencing [5]. 
Accurate determination of the HCV genotypes is essential for the 
selection of proper antiviral drugs and treatment regimens in HCV-infected 
individuals [9]. Treatment response also depends on HCV subgenotypes [10]. 
In Japan, the choice of antiviral regimen against HCV is generally based on 
the results of HCV serotyping as the national health insurance system 
currently approves only HCV serotyping methods [11]. Although previous 
reports indicate that the detection rate of serotyping is generally high and the 
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risk of misdiagnosis is considered rare [11], we have experienced few cases 
with misidentified genotypes in the treatment of hepatitis C. It is important to 
elucidate the mechanism responsible for the discrepancy between HCV 
genotyping based on directly sequencing of the HCV genome and HCV 
serotyping by enzyme immunoassay (EIA). 
In the present study, we described cases with discrepant results between 
HCV genotyping and serotyping assays that were based on the 5'-untranslated 
region (5'-UTR) and NS4 regions, respectively. Sanger sequencing was 
performed for the HCV core and NS4 regions, and deep sequencing was 
conducted for HCV NS4 regions to study the validity of the serotyping and 
genotyping results.  
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2. PATIENTS AND METHODS 
2.1. Study Population 
 Sera were obtained from 18 Japanese patients (11 males and 7 females) 
with chronic HCV infection and were stored at -20 °C until testing at Chiba 
University, Graduate School of Medicine. These patients had been previously 
serotyped when the direct-acting antiviral agents (DAAs) were not available. 
They were genotyped at the time of DAA treatment; however, discrepant 
results between HCV genotyping and serotyping were observed in all of these 
samples. All specimens were HCV RNA-positive by the Taqman reverse 
transcriptase-polymerase chain reaction (RT-PCR) assay (Roche Diagnostics, 
Tokyo, Japan), with levels ranging from 1.2 to 7.5 log IU/mL, and were 
negative for HBsAg or anti-HIV by ELISA. There was no sign of 
hepatocellular carcinoma in any of the patients, although Patient No. 7 and 14 
had histories of cirrhosis. More clinical information is described in Table 1. 
This study was approved by ethics committee of Chiba University, Graduate 
School of Medicine (No.415/1753/2153). Participation in the study was posted 
at our institutions. 
2.2. HCV Genotyping and Serotyping Assays 
HCV genotyping was performed by RT-PCR followed by Sanger direct 
sequencing at 5'-UTR of the HCV genome, except Sample No. 17, which was 
determined by the type-specific PCR method in the core region [12]. HCV 
serotyping was determined by detecting antibodies against group-specific 
recombinant protein for serotypes 1 and 2 in the putative HCV NS4 protein 
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region by an EIA that is commonly used in Japan [11]. According to this assay, 
HCV serotypes 1 and 2 correspond to HCV genotypes 1a/1b and 2a/2b, 
respectively. The results were described as “not determined” when no 
antibody could be detected and as “mixed” when both antigens reacted with 
serum samples. 
2.3. HCV RNA Extraction and RT-PCR 
Briefly, total RNA was extracted from 200 µL of sera by the High Pure 
Viral RNA Kit (Roche, Mannheim, Germany). cDNA was synthesized from 
viral RNA using SuperScript III First-Strand Synthesis SuperMix (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. The 
presence of HCV RNA in serum was confirmed by nested RT-PCR using 
primers of the 5'-UTR-core; Sc2 (sense; 5'-
GGGAGGTCTCGTAGACCGTGCACCATG-3', nucleotide position 318-
344) and Ac2 (antisense; 5'-GAGMGGKATRTACCCCATGAGRTCGGC-3', 
758-732) [12] and primers of NS4 regions; 5668 (sense; 5'-
ATGCATGTCRGCTGAYCTGGA-3', 5282-5302) and 007 (antisense; 5'-
AACTCGAGTATCCCACTGATGAAGTTCCACAT-3', 5665-5634) [22] in 
the first round. Two microliters of cDNA were amplified for 40 cycles with 
the following parameters: a preliminary 20 cycles of amplification at 94 °C for 
1 min (denaturing), 45 °C for 1 min (annealing) and 72 °C for 1 min 
(extension), followed by 20 additional cycles at 94 °C for 1 min, 55 °C for 1 
min and 72 °C for 1 min using the HotStarTaq Master Mix Kit (QIAGEN, 
Hilden, Germany). For second-round PCR, 2 µL of first-round PCR product 
were amplified for 35 cycles; each cycle consisted of 94 °C for 1 min, 55 °C 
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for 1 min and 72 °C for 1 min using HotStarTaq Master Mix Kit (QIAGEN) 
with primers of the 5'-UTR-core; S7 (sense; 5'-
AGACCGTGCACCATGAGCAC-3', 330-349) and A5 (antisense; 5'-
TACGCCGGGGGTCAKTRGGGCCCCA-3', 684-660) [12] or those of NS4 
regions; 865 (sense; 5'-CTGGAGGTTATCACNAGCACNTGG-3', 5298-
5321) and 220 (antisense; 5'-CACATGTGCTTCGCCCAGAA-3', 5638-5619) 
[22]. Nucleotide positions are described according to the sequence H77 
(Accession No. AF009606). Two rounds of amplification were performed on 
TaKaRa PCR Thermal Cycler Dice (Takara, Otsu, Japan). 
2.4. Cloning and Sanger Sequencing 
 Cloning of each PCR product into the TOPO vector (Invitrogen) was 
carried out using the TOPO TA Cloning Kit (Invitrogen) according to the 
manufacturer’s instructions. Up to 5 different clones were picked up for 
sequencing. Inserted fragments were confirmed by colony PCR using M13 
primers (sense, 5'-GTAAAACGACGGCCAG-3', and antisense, 5'-
CAGGAAACAGCTATGAC-3') with the following conditions: amplification 
for 30 cycles at 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min. PCR 
products were purified by the QIAquick PCR Purification Kit (QIAGEN), and 
submitted to Sanger DNA sequencing using an ABI3730XL DNA analyzer 
(Applied Biosystems, Waltham, MA, USA). Obtained sequences were aligned 
and phylogenetic analysis was performed using Genetyx software (Genetyx 
Corp., Tokyo, Japan). Reference sequences for each genotype were used as 
follows: AF009606 (H77) for genotype 1a; D10934 (HC-C2), D90208 (HCV-
J) and AJ238799 (Con1) for HCV genotype 1b; AB047639 (JFH-1) and 
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D00944 (HC-J6) for HCV genotype 2a; and AY232731 (MD2b1-2) and 
D10988 (HC-J8) for HCV genotype 2b [13]. The consensus sequence for each 
sample was determined from the cloned sequence data. The sequences 
determined in this study have been deposited in the GenBank database 
(Accession Nos. LC131493-LC131642, LC191872-LC191891). 
2.5. Deep Sequencing 
 The MiSeq platform (Illumina, San Diego, CA, USA) was used to 
analyze the HCV NS4 region, which was amplified by nested PCR using 
adaptor primers (sense, 5'-TCGTCGGCAGCGTCAGATGTG 
TATAAGAGACAGCTGGAGGTTATCACNAGCACNTGG-3', and 
antisense, 5'-GTCTCGTGGGCT 
CGGAGATGTGTATAAGAGACAGCACATGTGCTTCGCCCAGAA-3') 
with a KAPA HiFi HotStart ReadyMix PCR kit (KAPA BIO, Boston, MA, 
USA). PCR for the first round was 5 min at 95 °C; followed by 30 cycles for 
30 s at 95 °C, 30 s at 65 °C and 30 s at 72 °C. Purified PCR products were 
amplified using different sets of index primers in the Nextera XT Index kit 
(Illumina) for each sample. The PCR conditions for the amplification were 
95 °C for 3 min, followed by 8 cycles of 95 °C for 30 s, 55 °C for 30 s and 
72 °C for 30 s with a final extension of 72 °C for 5 min. After purification, the 
products were quantified using the Quant-iT PicoGreen double-stranded DNA 
(dsDNA) Reagent and Kit (Invitrogen) according to the manufacturer’s 
instructions. Paired-end sequencing was conducted on the Illumina MiSeq 
platform using a MiSeq Reagent Kit Nano v2 500 cycles (Illumina) according 
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to the manufacturer’s protocol. A MiSeq v2 Reagent Kit 500 cycles (Illumina) 
was used in No. 13, 14 and JFH-1 for control. 
2.6. Data Analysis of Deep Sequencing 
 After filtering by PANDAseq (v2.8) with the parameters “-L 300 -L 200” 
[29], an average of 70,157 reads was produced from each sample by the Nano 
kit while an average of 937,428 reads was produced by the standard kit. Each 
read was aligned against reference HCV genomes (H77, HCV-J, HC-J6 and 
HC-J8) using BLASTN (v2.2.28+) with the parameters “-evalue 1e-4–task 
blastn” [30]. Reference sequences with non-identical genotypes to samples 
were also included (D17763 (NZL1) for HCV genotype 3a, Y11604 (ED43) 
for 4a, Y13184 (EUH1480) for 5a, Y12083 (EUHK2) for 6a and EF108306 
(QC69) for 7a, respectively) [13]. Mixed infection was identified by the 
generation of multiple contigs against two or more reference genomes. For 
control experiments, HCV RNA was prepared from conditioned medium on 
Huh7 cells transfected with HCV JFH-1 [1] and was subjected to deep 
sequencing. Among 994,646 hit reads to the references, 990,097 reads 
(99.54%) were correctly assigned to the original JFH-1 sequences. When HC-
J6 was used as a reference of genotype 2a, 988,099 (99.42%) were correctly 
assigned to genotype 2a, while 4058 reads (0.41%) were assigned as genotype 
2b, which were regarded as sequencing errors. Based on these data, the 
threshold for the detection of minor populations with different genotypes was 
set at 0.5%.  
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3. RESULTS 
3.1. Patients’ Characteristics 
 In the present study, the patients consisted of 11 males and 7 females 
with a mean age of 62.2 years (Table 1). Among these 18 patients, histories of 
multiple intravenous injections, tattooing and blood transfusion were observed 
in 4, 5 and 2 patients, respectively. Family histories of liver diseases existed in 
four patients, of whom three were anti-HCV positive. Only one patient (No. 
18) had very low HCV RNA (<1.2 logIU/mL). 
3.2. HCV Genotyping and HCV Serotyping 
 Among 18 HCV isolates, HCV genotyping assays judged 4, 5 and 9 
isolates as HCV genotypes 1b, 2a and 2b, respectively (Table 2). Results of 
HCV serotyping are also shown in Table 2. Among four isolates of HCV 
genotype 1b; 2, 1 and 1 were judged as HCV serotype 2, not determined and 
mixed, respectively. Among five isolates of HCV genotype 2a; 3, 1 and 1 
were judged as HCV serotype 1, not determined and mixed, respectively. 
Among nine isolates of HCV genotype 2b; 6 and 2 were judged as HCV 
serotype 1 and not determined, respectively. For No. 17, genotype could not 
be determined by the type-specific PCR method in the core region [12], thus 
included in the study. This sample was determined as serotype 2, consistent 
with the sequencing results of genotype 2b.  
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3.3. Sanger Sequencing Results of Clones from HCV Core and NS4 
Regions 
 Table 2 shows the Sanger sequencing results in the core and NS4 
regions, respectively. In 16 of 18 samples, both results of cloned sequencing in 
the core and NS4 regions were consistent with the HCV genotyping by 5'-
UTR, but not with those of HCV serotyping. PCR amplification for one isolate 
(No. 18) could not be performed for core and NS4 regions due to the low titer 
of HCV RNA. Nucleotide sequences of the HCV core region obtained by 
sequencing were compared with those of reference sequences (Table 3). 
Nucleotide sequences and amino acid sequences of HCV NS4 regions were 
also compared with those of reference sequences (Tables 4 and 5). Sequence 
identity was generally high within the same subgenotype and higher in the 
core region than in the NS4 regions. 
3.4. Cloning Analysis of NS4 Epitope Regions 
 Epitope regions of NS4 antigen were described previously [14]. To 
examine whether the variations of NS4 epitope regions could affect the 
enzyme immunoassay results, amino acids of epitope regions in each clone 
were compared with those of group specific peptides 1 and 2 (Table 5B, C). 
Except for a few variations between amino acid sequences of the five clones, 
most of the sequences were the same within each sample. In comparison with 
the reference peptide, there were several amino acid variations in each sample 
except in No. 8. However, only a few cases had same amino acid as the 
reference of different genotypes (underlined in Table 5B, C), and each 
sequence was much closer to the reference peptide with the same genotype. 
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3.5. Results of HCV Genotyping by Deep Sequencing in NS4 Regions 
 Genotyping results investigated by deep sequencing of HCV NS4 
regions using the MiSeq Illumina sequencing method are shown in Figure 1 
and Table 6. For all 17 samples, more than 99% of the sequence reads were 
assigned to the same genotype, as with the genotyping results by other 
methods. The results were quite similar when different sequencing kits were 
compared between the nano kit and standard kit, within the same samples (No. 
2, 7 and 17) (data not shown). Among the 17 samples, genotype 2a (No. 5) 
and genotype 2b (No. 13) had minor populations assigned to different 
genotypes (genotype 2b and 2a, respectively) from major populations and 
were considered as mixed infection. The prevalence of these minor 
populations was between 0.5% and 1% (457 reads (0.58%) for Sample 5 and 
5010 reads (0.57%) for Sample 13). These minor populations are unlikely to 
be related to the serotyping results, because serotype 1 was detected from both 
samples (Table 2).  
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4. DISCUSSION 
The distribution of HCV genotypes is different among individuals with 
different infection routes such as blood transfusion, intravenous drug use and 
tattooing. In Japan, HCV genotype 1b had been associated with blood 
transfusion, whereas genotypes 2a and 2b were associated with injections or 
tattooing [15]. In the present study, 14 of 18 patients were confirmed as HCV 
genotype 2, supporting the previous report that described the NS4-based 
serotyping assay had lower concordance for genotype 2b specimens [16]. 
Among these 14 patients, seven (50%) had a history of intravenous injection 
or tattooing. These patients are considered to be multiple HCV-exposed 
individuals, and some of them might have been exposed to mixed infection 
with different HCV genotypes and subtypes. 
 In the present study, the same genotype was detected by cloned Sanger 
sequencing at the core and NS4 regions of the HCV genome as the genotype 
determined by 5'-UTR. No case was detected as mixed infection. As the 
possibility of the coexistence of a few minor variants could not be completely 
ruled out because only five clones were analyzed in this study, we further 
examined this possibility by the deep sequencing method. Deep sequencing of 
the HCV NS4 region produced large sequence depth ranging from 45 to 993 
thousands of reads from each sample. In all 17 cases of the present study, 
more than 99% of the reads were assigned to the same genotype as determined 
by other genotyping methods. Furthermore, in two of the 17 samples, a minor 
population of sequences with different HCV subgenotypes was detected, 
suggesting the possibility of mixed infection in these samples. It is difficult to 
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detect minor variants, which is between 0.5% and 1%, by the standard cloning 
method. Deep sequencing could rapidly and easily detect minor variants with 
a large sequence depth compared to the cloning method. As for sequencing 
error, our study using the JFH-1 clone revealed that up to 0.4% of reads were 
assigned to incorrect genotype (2b), consistent with a previous report 
describing a sequencing error rate of below 0.4% in the Illumina platform [17]. 
However, Thomson et al. [18] suggested that the detection of minority variants 
is less reliable at lower ratios. The cases of mixed infection with different 
HCV genotypes, as well as the recombinant forms of HCV are very rare, even 
in a highly exposed group, such as intravenous drug users (IVDU) [19]. 
 Among the 18 cases, 11 were confirmed to show different HCV 
serotyping results from HCV genotyping; two cases showed HCV genotype 
1b with HCV serotype 2; while nine cases showed HCV genotype 2 with 
HCV serotype 1. Compared to the core region, nucleotide sequence variations 
in the NS4 region were more commonly existing between samples within the 
same genotype (Tables 3 and 4). We examined the possibility that variations 
of the amino acid sequence could affect the serotyping results. Both consensus 
sequence (Table 5A) and cloning analysis in the NS4 region (Table 5B,C) 
showed that although several amino acid variations existed when compared 
with the HCV genotype-specific reference peptide, each sequence was much 
closer to the reference peptide with the same genotype. It should be noted that 
the error rate of Taq DNA polymerase is approximately 2 × 10
−5
, estimating 
that one nucleotide error could appear in 50% of the amplified DNA 
molecules by nested PCR. Furthermore, comparative analysis with the control 
group will be needed to better understand the mechanism of discrepancy. 
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 Among the 18 HCV specimens serotyped in our series, four samples 
(22.2%) were defined as “not determined”. It has been suggested that HCV 
serotyping analysis provides an indirect typing method based on the 
production of type-specific antibodies by the infected host. Therefore, the 
sensitivity of HCV serotyping depends on the immune response of the HCV-
infected host. Therefore, the possibility that some of the patients with HCV 
infection did not produce antibody against NS4 protein should be considered. 
By the HCV serotyping assay, two of the 18 patients (11.1%) had mixed 
reactions. Multiple exposures to different HCV strains could be one possible 
mechanism for these findings, although the possibility of non-specific reaction 
also exists. For such cases, instead of HCV serotyping, HCV genotype testing 
can be a good alternative method. 
 A major limitation of our study is that we could not describe the 
sensitivity and concordance between HCV serotyping and genotyping data in 
the entire cohort due to lack of a comparable group. Previous studies [11, 20] 
using the same NS4 antigen (C14) as ours showed that the sensitivity of 
serotypes 1 and 2 is 95.8%-100%, and there was no discordant case. We 
repeated the initial serotyping assay using the same antigen with the newly-
updated chemiluminescent EIA system (HISCL HCV Gr reagents, Sysmex, 
Japan). According to the manufacturer’s instruction, the sensitivity of the new 
system is 84.4%, and the serotyping results showed 100% concordance with 
those of the older system. Our re-serotyping analysis showed that new system 
could correctly detect type 2-specific antibody in six samples (No. 6, 8, 10, 12, 
17 and 18) and type 1 antibody in two samples (No. 2 and 4). However, it 
could not detect any antibodies in eight cases, showed the incorrect serotype in 
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one case (No. 14) and mixed serotype in one case (No. 11). These results 
suggest that comparing different serotyping systems would be useful to 
understand the discrepant cases further. 
 After the identification of serotype-specific linear epitopes in the core 
and NS4 region [11, 14], several serotyping systems have been reported using 
peptides corresponding to these regions. Besides the C14 serotyping system 
we used, the MUREX HCV Serotyping 1-6 assay (Abbott Diagnostics) has 
been developed [21] using type-specific NS4 antigen corresponding to HCV 
types 1-6. Prescott et al. [22] reported that 15 discrepant cases (151/166) could 
be detected using the old version of this assay (HC02). According to the 
instructions, the concordance (96.12%) of the new version (2G26) becomes 
higher than an earlier version (HC02) (90.96%), while the sensitivity of 
serotypes 1 and 2 is 76.8% and 75.5% in the new version. The RIBA HCV 
serotyping assay (Chiron Corporation) [16, 23, 24] detected anti-HCV 
antibodies against five synthetic peptides from the NS4 region and three 
peptides from the core region, and it has been reported that the 
sensitivity/concordance of serotypes 1 and 2 is 84.7%-96.5%/96.2%-100% 
and 82.4%-100%/93.4%-100%, respectively. Taken together, serotyping 
generally shows high concordance with genotyping. However, attention 
should be paid to the fact that there can be occured cases with no response to 
the antigen and also with discrepancy even if they can be regarded as 
uncommon events based on previous studies. 
 Only sequence analysis of specific gene regions of the HCV genome 
that are predictive of HCV genotype was completely reliable for HCV 
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genotyping [25]. There are several genotyping methodologies available, such 
as sequencing, primer-specific PCR, real-time PCR and the line probe assay. 
Chantratita et al. [26] compared two PCR-based line probe assays and recently 
reported that the six HCV genotyping 9G test showed overall sensitivity and 
specificity higher than 92.5% and 99.4%, respectively. On the other hand, this 
method based on PCR may not be correctly estimated in cases with low-level 
viremia, such as No. 18 in this study, or if serum samples have not been stored 
correctly [27]. Meanwhile, one sample (No. 17) could not be genotyped by the 
HCV genotype-specific PCR method. In this case, even small sequence 
variations in the primer region could affect the results due to high sequence 
similarity in this region (Table 3). 
Serological methods are based on the detection of antibodies against 
HCV serotype-specific epitopes and are easier and faster for determining HCV 
serotypes. It is possible that HCV serotyping may allow the determination of 
HCV types of both past and present infection. Moreover, its high performance 
on samples with low viral load offers an obvious advantage over the 
genotyping methods. The cost of the HCV serotyping method is less than that 
of HCV genotyping. ELISA of the HCV serotyping method is seldom 
associated with the risk of contamination. Thus, HCV serotyping is 
particularly suitable for epidemiologic studies. 
 Treatment outcomes of patients are shown in Table 7. In two of four 
patients with HCV genotype 1b, treatment with daclatasvir plus asunaprevir 
for 24 weeks could lead to sustained virologic response at 24 weeks after the 
stoppage of treatment (SVR24). In four of five patients with HCV genotype 2a, 
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treatment with sofosbuvir plus ribavirin was performed for 12 weeks, and all 
four patients achieved SVR24. Among the total of nine patients with HCV 
genotype 2b, five were treated with interferon-free or interferon-including 
regimens and achieved SVR24. Although six patients (No. 1, 2, 3, 4, 9, 16) 
had been treated with interferon-including treatments without DAAs based on 
serotyping results, some patients (No. 2, 4, 9), developed relapse after 
completing the treatment course, and others (No. 1, 3, 16) had no response. 
 Better treatment outcome can be obtained when the treatment is based 
on HCV genotyping results. For example, Patient No. 2 had been a candidate 
for sofosbuvir and ribavirin regimen based on the serotyping results (serotype 
2), but the patient was treated with daclatasvir and asunaprevir regimen after 
getting the genotyping result of genotype 1b and achieved SVR24. Sohda et al. 
[28] reported the non-response to daclatasvir and asunaprevir therapy in 
patients coinfected with hepatitis C virus genotypes 1 and 2.  
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5. CONCLUSION 
Although the HCV serotyping method is a widely applicable method 
especially when many samples are to be tested, there are some discrepant 
cases, as well. Currently, there are several serotyping systems with high 
accuracy available. Using the latest system and combining different methods 
should minimize the risk of discrepancy. Rapid genotyping systems can be a 
better alternative to serotyping, although it is still costly. The present study 
highlighted ultra-deep sequencing, and it may be useful for the diagnosis of 
patients with mixed HCV genotypes. Until the availability of effective 
antiviral regimens for the pangenotypes of HCV, HCV genotyping should be 
correctly determined before antiviral therapy, especially in certain regimens, 
for which the efficacy is dependent on HCV genotypes.  
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7. TABLES 
Table 1. Background of patients enrolled in the present study 
No. Age/Sex Risk Factors 
Family Histories of 
Liver Diseases 
HCV RNA  
(Log IU/mL) 
ALT 
(IU/L) 
PLT 
(10
4/μL) 
ALB 
(g/dL) 
Total 
Bilirubin 
(mg/dL) 
AFP 
(ng/mL) 
1. 56/F Unknown − 6.6 52 19.6 4.1 0.5 20.2 
2. 71/M None + 7.5 61 12 4.6 1.3 2.3 
3. 66/M Tattoo − 5.9 52 9.3 3.8 1.0 8.1 
4. 51/M Blood transfusion − 6.7 53 26.2 4.5 0.5 6.1 
5. 61/F None + >5.9 14 18.7 4.1 0.9 3.4 
6. 81/M None + 6 253 12.3 4.3 0.6 10.4 
7. 74/M IVDU − 6.4 62 9.1 3.7 0.9 11.5 
8. 57/F Unknown − >5.9 17 21.3 4.4 0.5 6 
9. 50/M IVDU − 7.2 24 15.4 4.3 0.7 3 
10. 47/M Tattoo and IVDU − 6.8 52 18.5 4 0.5 2.6 
11. 58/F Tattoo − >5.9 22 19.3 4.8 1.1 2.7 
12. 65/F Tattoo − 7 18 22.3 4.7 0.7 2.2 
13. 71/F None − 6.2 16 17.3 4.2 0.6 2.6 
14. 62/M Blood transfusion − 6.4 21 15.7 4.6 0.4 5.1 
15. 58/M Unknown − NA 23 13.9 3.4 0.3 3.4 
16. 62/F None + 6 38 19.5 4.3 0.6 2.5 
17. 57/M Tattoo − 4.4 130 13.7 4.1 0.7 6 
18. 72/M IVDU − <1.2 21 13.2 4.1 0.5 3.6 
No., patient number; HCV, hepatitis C virus; ALT, alanine transaminase; PLT, platelet counts; ALB, albumin; AFP, α-fetoprotein; M, 
male; F, female; −, negative; +, positive; NA, not available.  
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Table 2. Comparison between the results of serotyping, genotyping, Sanger sequencing and deep sequencing methods for   
discrepant samples 
 
No. Serotyping Genotyping (5′-UTR) 
Genotyping by Cloned Sanger Sequencing 
Genotyping by Deep Sequencing (NS4) 
Core NS4 
1. 2 1b 1b 1b 1b 
2. 2 1b 1b 1b 1b 
3. ND 1b 1b 1b 1b 
4. Mixed 1b 1b 1b 1b 
5. 1 2a 2a 2a 2a + 2b * 
6. 1 2a 2a 2a 2a 
7. 1 2a 2a 2a 2a 
8. ND 2a 2a 2a 2a 
9. 1 2b 2b 2b 2b 
10. 1 2b 2b 2b 2b 
11. 1 2b 2b 2b 2b 
12. 1 2b 2b 2b 2b 
13. 1 2b 2b 2b 2a * + 2b 
14. 1 2b 2b 2b 2b 
15. ND 2b 2b 2b 2b 
16. ND 2b 2b 2b 2b 
17. 2 ND ** 2b 2b 2b 
18. Mixed 2a ND ND ND 
ND, not determined; Mixed, co-reaction to serotypes 1 and 2. * Minor different genotypes; ** this sample was included in the study due 
to the failure for genotyping by type-specific PCR method in the core region, but later found as genotype 2b by sequence-based 
genotyping.  
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Table 3. Comparison between HCV core nucleotide sequences obtained from discrepant samples by cloned Sanger 
sequencing and reference sequences (Ref.) specific for each genotype. (A) Identity between core nucleotide 
sequences of genotype 1b obtained by sequencing (5 clones) and reference sequences of genotype 1 (1a and 1b); 
(B) Identity between core nucleotide sequences of genotype 2a obtained by sequencing (5 clones) and reference 
sequences of genotype 2a; (C) Identity between core nucleotide sequences of genotype 2b obtained by sequencing 
(5 clones) and reference sequences of genotype 2b. 
(A) 
 
Ref. H77 HC-C2 HCV-J  Con1 No. 1 No. 2 No. 3 No. 4 
H77 
100%  
(309/309) 
       
HC-C2 
92.6% 
 (286/309) 
100%  
(309/309) 
      
HCV-J 
92.2%  
(285/309) 
97.1%  
(300/309) 
100% 
 (309/309) 
     
Con1 
92.2% 
 (285/309) 
97.4% (3 
01/309) 
97.1% 
 (300/309) 
100% 
 (309/309) 
    
No. 1 
91.8%  
(1419/1545) 
97.4%  
(1505/1545) 
96.7%  
(1494/1545) 
97.8% 
 (1511/1545) 
98.9%  
(4585/4635) 
   
No. 2 
90.8%  
(1403/1545) 
96.6%  
(1493/1545) 
97.0%  
(1498/1545) 
96.0% 
 (1483/1545) 
95.9%  
(7405/7725) 
99.8% 
 (4627/4635) 
  
No. 3 
91.8%  
(1419/1545) 
97.7%  
(1509/1545) 
98.1%  
(1516/1545) 
97.2% 
 (1501/1545) 
97.0%  
(7495/7725) 
96.9% 
 (7485/7725) 
99.5% 
 (4613/4635) 
 
No. 4 
92.3% 
 (1426/1545) 
96.6%  
(1492/1545) 
97.5%  
(1506/1545) 
97.2% 
 (1502/1545) 
96.8%  
(7480/7725) 
96.4%  
(7450/7725) 
97.4% 
 (7525/7725) 
99.7%  
(4619/4635) 
Reference sequences for each genotype were used as follows: H77 for HCV genotype 1a; HC-C2, HCV-J and Con1 for HCV genotype 
1b; JFH-1 and HC-J6 for HCV genotype 2a; MD2b1-2 and HC-J8 for HCV genotype 2b [13].  
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(B) 
Ref. JFH-1 HC-J6 No. 5 No. 6 No. 7 No. 8 
JFH-1 100% (309/309)      
HC-J6 94.5% (292/309) 100% (309/309)     
No. 5 94.5% (1460/1545) 96.1% (1486/1545) 98.8% (4581/4635)    
No. 6 94.6% (1461/1545) 96.8% (1496/1545) 95.3% (7365/7725) 99.7% (4621/4635)   
No. 7 93.3% (1442/1545) 95.6% (1477/1545) 95.0% (7339/7725) 94.4% (7290/7725) 97.4% (4515/4635)  
No. 8 94.8% (1465/1545) 96.8% (1496/1545) 96.1% (7424/7725) 95.9% (7405/7725) 94.8% (7324/7725) 99.4% (4605/4635) 
(C) 
Ref. HC-J8 MD2b1-2 No. 9 No. 10 No. 11 No. 12 No. 13 No. 14 No. 15 No. 16 No. 17 
HC-J8 
100% 
(309/309) 
          
MD2b1-2 
97.4% 
(301/309) 
100% 
(309/309) 
         
No. 9 
95.6% 
(1477/1545) 
95.6% 
(1477/1545) 
99.6% 
(4615/4635) 
        
No. 10 
96.9% 
(1497/1545) 
97.4% 
(1505/1545) 
95.5% 
(7375/7725) 
98.7% 
(4574/4635) 
       
No. 11 
96.0% 
(1483/1545) 
96.1% 
(1485/1545) 
94.6% 
(7310/7725) 
96.6% 
(7466/7725) 
98.6% 
(4572/4635) 
      
No. 12 
96.5% 
(1491/1545) 
97.2% 
(1501/1545) 
96.3% 
(7439/7725) 
97.5% 
(7535/7725) 
96.5% 
(7452/7725) 
98.8% 
(4581/4635) 
     
No. 13 
95.5% 
(1475/1545) 
95.7% 
(1479/1545) 
93.7% 
(7328/7725) 
94.5% 
(7300/7725) 
94.3% 
(7285/7725) 
94.7% 
(7316/7725) 
97.7% 
(4528/4635) 
    
No. 14 
97.5% 
(1506/1545) 
97.5% 
(1506/1545) 
95.8% 
(7400/7725) 
96.8% 
(7478/7725) 
96.0% 
(7416/7725) 
96.8% 
(7478/7725) 
95.5% 
(7377/7725) 
99.6% 
(4616/4635) 
   
No. 15 
96.4% 
(1489/1545) 
96.0% 
(1483/1545) 
95.5% 
(7375/7725) 
95.8% 
(7400/7725) 
95.4% 
(7372/7725) 
96.0% 
(7413/7725) 
94.8% 
(7323/7725) 
95.8% 
(7400/7725) 
99.2% 
(4598/4635) 
  
No. 16 
95.0% 
(1468/1545) 
95.5% 
(1476/1545) 
95.2% 
(7352/7725) 
95.5% 
(7381/7725) 
94.8% 
(7325/7725) 
95.6% 
(7384/7725) 
93.8% 
(7246/7725) 
95.2% 
(7354/7725) 
95.0% 
(7340/7725) 
99.1% 
(4591/4635) 
 
No. 17 
94.6% 
(1462/1545) 
95.3% 
(1472/1545) 
94.2% 
(7280/7725) 
94.8% 
(7320/7725 
93.3% 
(7205/7725) 
94.8% 
(7320/7725) 
93.1% 
(7192/7725) 
94.7% 
(7316/7725) 
94.1% 
(7270/7725) 
94.0% 
(7265/7725) 
99.4% 
(4609/4635) 
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Table 4. Comparison between HCV NS4 nucleotide sequences obtained from discrepant samples by cloned Sanger 
sequencing and reference sequences (Ref.) specific for each genotype. (A) Identity between NS4 nucleotide 
sequences of genotype 1b obtained by sequencing (5 clones) and reference sequences of genotype 1 (1a and 1b); 
(B) Identity between NS4 nucleotide sequences of genotype 2a obtained by sequencing (5 clones) and reference 
sequences of genotype 2a; (C) Identity between NS4 nucleotide sequences of genotype 2b obtained by sequencing 
(5 clones) and reference sequences of genotype 2b. 
(A) 
Ref. H77 HC-C2 HCV-J Con1 No. 1 No. 2 No. 3 No. 4 
H77 
100%  
(297/297) 
       
HC-C2 
76.1% 
 (226/297) 
100% 
 (297/297) 
      
HCV-J  
78.1%  
(232/297) 
90.9% 
 (270/297) 
100% 
 (297/297) 
     
Con1 
77.1% 
 (229/297) 
88.9% 
 (264/297) 
90.9% 
 (270/297) 
100% 
 (297/297) 
    
No. 1 
77.3%  
(1148/1485) 
89.4%  
(1328/1485) 
94.3%  
(1400/1485) 
91.0% 
 (1352/1485) 
98.2%  
(4376/4455) 
   
No. 2 
76.4% 
 (1134/1485) 
88.8%  
(1319/1485) 
89.6%  
(1331/1485) 
87.8%  
(1304/1485) 
88.7% 
 (6585/7425) 
99.9%  
(4451/4455) 
  
No. 3 
74.7% 
 (1110/1485) 
90.9%  
(1350/1485) 
89.4% 
 (1328/1485) 
90.4% 
 (1343/1485) 
88.9% 
 (6601/7425) 
88.5%  
(6570/7425) 
99.2% 
 (4421/4455) 
 
No. 4 
77.5%  
(1151/1485) 
92.3% 
 (1370/1485) 
92.3%  
(1370/1485) 
92.3%  
(1371/1485) 
91.9%  
(6825/7425) 
91.6%  
(6800/7425) 
93.5% 
 (6940/7425) 
99.7%  
(4441/4455) 
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(B) 
Ref. JFH-1 HC-J6 No. 5 No. 6 No. 7 No. 8 
JFH-1 100% (297/297)      
HC-J6 88.6% (263/297) 100% (297/297)     
No. 5 89.3% (1326/1485) 91.6% (1361/1485) 98.5% (4389/4455)    
No. 6 91.2% (1355/1485) 91.7% (1362/1485) 94.0% (6980/7425) 98.5% (4389/4455)   
No. 7 87.8% (1304/1485) 90.8% (1349/1485) 92.3% (6850/7425) 90.9% (6748/7425) 96.6% (4304/4455)  
No. 8 90.6% (1346/1485) 92.1% (1368/1485) 92.3% (6854/7425) 90.7% (6735/7425) 91.2% (6771/7425) 99.2% (4419/4455) 
(C) 
Ref. HC-J8 MD2b1-2 No. 9 No. 10 No. 11 No. 12 No. 13 No. 14 No. 15 No. 16 No. 17 
HC-J8 
100% 
(297/297) 
          
MD2b1-2 
94.6% 
(281/297) 
100% 
(297/297) 
         
No. 9 
92.4% 
(1372/1485) 
89.7% 
(1332/1485) 
99.7% 
(4442/4455) 
        
No. 10 
91.9% 
(1365/1485) 
93.1% 
(1383/1485) 
88.8% 
(6590/7425) 
98.7% 
(4397/4455) 
       
No. 11 
93.9% 
(1395/1485) 
93.9% 
(1395/1485) 
89.8% 
(6665/7425) 
93.3% 
(6925/7425) 
98.9% 
(4407/4455) 
      
No. 12 
95.0% 
(1411/1485) 
95.9% 
(1424/1485) 
90.4% 
(6710/7425) 
94.1% 
(6984/7425) 
95.3% 
(7073/7425) 
98.9% 
(4407/4455) 
     
No. 13 
92.4% 
(1372/1485) 
92.1% 
(1368/1485) 
89.9% 
(6675/7425) 
91.8% 
(6816/7425) 
92.7% 
(6883/7425) 
93.2% 
(6920/7425) 
99.8% 
(4446/4455) 
    
No. 14 
92.8% 
(1378/1485) 
92.9% 
(1380/1485) 
89.3% 
(6631/7425) 
93.1% 
(6913/7425) 
93.7% 
(6957/7425) 
93.9% 
(6972/7425) 
93.3% 
(6928/7425) 
99.2% 
(4419/4455) 
   
No. 15 
92.9% 
(1380/1485) 
91.6% 
(1360/1485) 
90.5% 
(6720/7425) 
92.3% 
(6856/7425) 
92.7% 
(6885/7425) 
93.8% 
(6965/7425) 
91.3% 
(6779/7425) 
92.7% 
(6883/7425) 
99.4% 
(4427/4455) 
  
No. 16 
92.0% 
(1366/1485) 
90.6% 
(1346/1485) 
90.2% 
(6695/7425) 
90.6% 
(6726/7425) 
91.1% 
(6765/7425) 
91.7% 
(6810/7425) 
92.4% 
(6861/7425) 
91.3% 
(6779/7425) 
90.8% 
(6740/7425) 
99.3% 
(4423/4455) 
 
No. 17 
89.6% 
(1330/1485) 
87.2% 
(1295/1485) 
89.7% 
(6660/7425) 
85.5% 
(6351/7425) 
87.3% 
(6484/7425) 
88.2% 
(6551/7425) 
89.4% 
(6638/7425) 
86.3% 
(6408/7425) 
86.3% 
(6406/7425) 
88.1% 
(6540/7425) 
98.2% 
(4375/4455) 
  
29 
 
Table 5. (A) Comparison between consensus NS4 amino acid sequences obtained from discrepant samples by cloned Sanger 
sequencing, group-specific peptides and reference sequences; (B) Comparison between epitope regions of NS4 
amino acid sequences from genotype 1b samples by cloned Sanger sequencing and those of group 1 peptide; 
(C) Comparison between epitope regions of NS4 amino acid sequences from samples of genotype 2a, 2b by 
cloned Sanger sequencing and those of group 2 peptide. 
(A) 
Group 1 Peptide FTTGSVVIVGRIILSGRPAVIPDREVLYREFDEMEECASHLPYIEQGMQLAEQFKQKALGLLQTATKHAEAAAPVVESKWRALET 
HC-C2 L...........V...............Q........G.........................I...Q.................  
HCV-J L...........................Q......................................Q................V  
Con1 L...............K..I......................................I........Q.............T..A  
No. 1 L...............K...........Q......................................Q............Q...A  
No. 2 L...................V................T.............................Q......M.....Q...A  
No. 3 L..................................................................Q.................  
No. 4 L...............K..................................................Q.................  
Group 2 peptide .A..C.S.I..LHINQ.AV.A..K....EA.........RAAL..E.QRI..ML.S.IQ....Q.S.Q.QDIK.A.QTS.PKV.Q  
JFH-1 LA..C.S.I..LHVNQ.VV.A..K....EA.........RAAL..E.QRI..ML.S.IQ....Q.S.Q.QDIQ.AMQAS.PKV.Q  
HC-J6 LA..C.C.I..LHVNQ.AV.A..K....EA.........RAAL..E.QRI..ML.S.IQ....Q.S.Q.QDIQ.A.QAS.PKV.Q  
No. 5 LA..C.S.I..LHINQ.AV.A..K....EA.........KAAL..E.QRI..ML.S.IQ....Q.S.Q.QDIQ.A.QAS.PKV.Q  
No. 6 LA..CVT.I..LHVNQ.AV.A..K....EA.........KAAL..E.QRI..ML.S.IQ....Q.S.Q.QDIQ.A.QAS.PKV.Q  
No. 7 LA..C.S.I..LHINQ.AV.A..K....EA.........KAAL..E.QRI..ML.S.IQ....Q.S.Q.QDIQ.A.QAS.PKV.Q  
No. 8 LA..C.S.I..LHINQ.AV.A..K....EA.........RAAL..E.QRI..ML.S.IQ....Q.S.Q.QDIQ.A.QAS.PKV.Q  
HC-J8 LA..CIS.I..LH.ND.VV.A..K.I..EA.........KAAL..E.QRM..ML.S.IQ....Q..RQ.QDIQ.AIQ.S.PK..Q  
MD2b1-2 LA..C.S.I...H.ND.AV.A..K....EA.........KAAL..E.QRM..ML.S.IQ....Q..RQ.QDIQ.AIQ.S.PK..Q  
No. 9 LA..CIS.I..LH.ND.VV.T..K....EA.........KAAL..E.QRM..ML.S.IQ....Q..RQ.QDIQ.AIQ.S.PK..Q  
No. 10 LA..CICSI...H.NDQVV.A..K....EA.........KAAL..E.QRM..ML.S.IQ....Q...Q.QDIQ.AIQ.S.PK..Q  
No. 11 LA..CIS.I...H.ND.VV.A..K.I..EA.........KAAL..E.QRM..ML.S.IQ....Q..RQ.QDIQ.AIQ.S.PK..Q  
No. 12 LA..CIS.I...H.NDHVV.A..K.I..EA.........KAAL..E.QRM..ML.S.IQ....Q..RQ.QDIQ.AIQ.S.PK..Q  
No. 13 LA..CIS.I..LH.ND.VV.A..K.I..EA.........KAAL..E.QRM..ML.S.IQ....Q...Q.QDIQ.A.Q.S.PK..Q 
No. 14 LA..CIS.I..LH.ND.VV.A..K.I..EA.........KAAL..E.QRM..ML.S.IQ....Q...Q.QDIQ.AIQ.S.PK..Q 
No. 15 LA..CIS.I..LH.NDHVV.A..K.I..EA.........KAAL..E.QRM..ML.S.IQ....Q...Q.QDIQ.TIQ.S.PK..Q  
No. 16 LA..CIS.I..VH.ND.VV.T..K.I..EA.........KAAL..E.QRI..ML.S.IQ....Q...Q.QDIQ.A.Q.S.PK..Q  
No. 17 LA..CIS.I..LH.ND.VV.T..K.I..EA.........KAAL..E.QRI..ML.S.IQ....Q..RQ.QDIQ.AMQ.S.PK..Q  
The same amino acids with group 1 peptide in each position are described as dots.  
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(B) 
No. Genotype Region 1 Region 2 
Group 1 Peptide RPAVIPDREVLYREFDEM ECASHLPYIEQGMQLAEQF 
1. 1b K-----------Q----- (5) ------------------- (5) 
2. 1b ----V------------- (5)  --T---------------- (5) 
3. 1b 
------------------ (3)  
------------------- (5) --V--------------- (1) 
---------------G-- (1) 
4. 1b 
K----------------- (3) 
------------------- (5) 
K-----------Q----- (2) 
Group 2 peptide -AV-A--K----EA---- ----RAAL--E-QRI--ML 
The same amino acids with group 1 peptides are indicated by dashes. Group 2 peptides are also shown in the bottom line. The numbers of 
clones with the same sequence patterns are indicated in the parentheses. The amino acids that are the same as those of reference peptides 
of different genotypes are underlined.  
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(C) 
No. Genotype Region 1 Region 2 
Group 2 Peptide RAVVAPDKEVLYEAFDEM ECASRAALIEEGQRIAEML 
5. 2a ------------------ (5) 
----K-------------- (4) 
---PK-------------- (1) 
6. 2a ------------------ (5) 
----K-------------- (4) 
----K---T---------- (1) 
7. 2a ------------------ (5) 
----K-------------- (4) 
------------------- (1) 
8. 2a ------------------ (5) ------------------- (5) 
9. 2b 
-V--T------------- (4) ----K---------M---- (4) 
-I--T------------- (1) --------------M---- (1) 
10. 2b 
QV---------------- (4) ----K---------M---- (4) 
QV-------I-------- (1) ----KV--------T---- (1) 
11. 2b 
-V-------I-------- (4) 
----K---------M---- (5) 
-VA------I-------- (1) 
12. 2b 
HV-------I-------- (4) 
----K---------M---- (5) 
HV-M-----I-------- (1) 
13. 2b -V-------I-------- (5) ----K---------M---- (5) 
14. 2b -V-------I-------- (5) ----K---------M---- (5) 
15. 2b 
HV-------I-------- (4) 
----K---------M---- (5) 
HV-------I----S--- (1) 
16. 2b -V--T----I-------- (5) 
----K-------------- (3) 
----K-----K-------- (1) 
----K-D------------ (1) 
17. 2b 
-V--T----I-------- (4) 
----K-------------- (5) 
-V--T----I-C------ (1) 
Group 1 peptide -PA-I--R----RE---- ----HLPY--Q-MQL--QF 
The same amino acids with group 2 peptides are indicated by dashes. Group 1 peptides are also shown in the bottom line. The 
numbers of clones with the same sequence patterns are indicated in the parentheses. The amino acids that are the same as 
those of reference peptides of different genotypes are underlined.  
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 Table 6. HCV genotypes by deep sequencing of HCV NS4 regions 
No. 
H-77  
(GT 1a) 
HCV-J  
(GT 1b) 
HC-J6  
(GT 2a) 
HC-J8  
(GT 2b) 
NZL1 (GT 3a), ED43 (GT 4a), 
EUH1480 (GT 5a), EUHK2 (GT 6a), 
QC69 (GT 7a) 
Total log10 
Reads 
1. <0.5% 99.40% <0.5% <0.5% <0.5% 4.9 
2. <0.5% 99.52% <0.5% <0.5% <0.5% 4.9 
3. <0.5% 99.49% <0.5% <0.5% <0.5% 4.9 
4. <0.5% 99.87% <0.5% <0.5% <0.5% 4.7 
5. <0.5% <0.5% 99.41% 0.58% * <0.5% 4.9 
6. <0.5% <0.5% 99.34% <0.5% <0.5% 4.8 
7. <0.5% <0.5% 99.92% <0.5% <0.5% 4.7 
8. <0.5% <0.5% 99.87% <0.5% <0.5% 4.7 
9. <0.5% <0.5% <0.5% 99.55% <0.5% 4.9 
10. <0.5% <0.5% <0.5% 99.87% <0.5% 4.9 
11. <0.5% <0.5% <0.5% 99.78% <0.5% 4.9 
12. <0.5% <0.5% <0.5% 99.80% <0.5% 4.8 
13. <0.5% <0.5% 0.57% * 99.26% <0.5% 5.9 
14. <0.5% <0.5% <0.5% 99.51% <0.5% 6.0 
15. <0.5% <0.5% <0.5% 99.57% <0.5% 4.9 
16. <0.5% <0.5% <0.5% 99.26% <0.5% 4.9 
17. <0.5% <0.5% <0.5% 99.32% <0.5% 4.8 
JFH-1 <0.5% <0.5% 99.42% <0.5% <0.5% 6.0 
GT, genotype; * Indicates minor populations  
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Table 7. Treatment outcomes with or without the direct-acting antiviral agents (DAAs) in the present study 
No. Treatment with DAAs 
Outcomes  
(with DAAs) 
Previous Treatment 
(without DAAs) 
Outcomes 
(Without DAAs) 
1. Daclatasvir plus asunaprevir for 24 weeks SVR (+) Null response 
2. Daclatasvir plus asunaprevir for 24 weeks SVR (+) Relapse 
3. NA NA (+) Null response 
4. NA NA (+) Relapse 
5. Sofosbuvir plus ribavirin for 12 weeks SVR (−) NA 
6. Sofosbuvir plus ribavirin for 12 weeks SVR (−) NA 
7. Sofosbuvir plus ribavirin for 12 weeks SVR (−) NA 
8. Sofosbuvir plus ribavirin for 12 weeks SVR (−) NA 
9. Sofosbuvir plus ribavirin for 12 weeks SVR (+) Relapse 
10. Telaprevir with peginterferon plus ribavirin SVR (−) NA 
11. Sofosbuvir plus ribavirin for 12 weeks SVR (−) NA 
12. Peginterferon plus ribavirin for 24 weeks SVR (−) NA 
13. NA NA (−) NA 
14. NA NA (−) NA 
15. NA NA (−) NA 
16. NA NA (+) Null response 
17. Sofosbuvir plus ribavirin for 12 weeks SVR (−) NA 
18. NA NA (−) NA 
SVR, sustained virological response; NA, not available; (−), not performed; (+), performed  
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8. FIGURE 
 
  
Figure 1. HCV genotypes (GTs) by deep sequencing of HCV NS4 regions. For each sample, only populations that exist at a 
frequency of >0.005 (red line) were shown by log-scale. No. 5 with the main genotype 2a had minor populations assigned to 
the different genotype 2b. No. 13 with genotype 2b had minor populations assigned to the different genotype 2a.
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